RT Journal Article SR Electronic T1 A novel retinoic acid analog, 4-Amino-2-Trifluoromethyl-Phenyl Retinate (ATPR) triggers differentiation and is effective in the treatment of Acute Promyelocytic Leukemia JF bioRxiv FD Cold Spring Harbor Laboratory SP 2020.07.09.194928 DO 10.1101/2020.07.09.194928 A1 Jing Bao A1 Yan Du A1 Lan-lan Li A1 Liang Xia A1 Fei-hu Chen YR 2020 UL http://biorxiv.org/content/early/2020/07/09/2020.07.09.194928.abstract AB Acute promyelocytic leukemia (APL), form RARĪ± fusion genes and proteins is one of the most prevalent forms of leukemia. 4-Amino-2-Trifluoromethyl-Phenyl Retinate (ATPR), a derivative of all-trans-retinoic acid (ATRA), is of potent functions in the induce of cell differentiation, growth arrest, and apoptosis. Nowadays, we aimed to investigate the therapeutic effect of ATPR on this APL pathological model, and whether the mechanism involves PI3K/AKT, ERK and Notch signaling. We established a human xenograft mouse model using NB4 cells and found that ATPR significantly increased the protein concentration in the CD11b and suppressed the PI3K/AKT signaling and activated the ERK and Notch signaling in tumor tissue. Collectively, these data suggest that ATPR shows antileukemic effects by regulating PI3K/AKT, ERK and Notch signaling.